RxDoctor Payments Data

Kimberly Coonfield, MD

Internal Medicine · Rosenberg, TXNPI 1588855761

Payments from drug & device makers

$1,415in general payments, 2019–2025

Across 53 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$432
  • Novo Nordisk$196
  • Dexcom, Inc.$153
  • Amgen$133
  • Lilly USA, LLC$113
  • AstraZeneca$66
  • plus $322 from 11 others

What the payments were for

  • Food & beverage$1,38598%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,415 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$136,352
Medicare patients
363
Services billed
1,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide200$319,161
JardianceEmpagliflozin156$184,248
EliquisApixaban90$112,147
TrulicityDulaglutide76$103,390
MounjaroTirzepatide66$96,872
JanuviaSitagliptin Phosphate40$47,165
Tresiba Flextouch U-200Insulin Degludec44$41,800
Soliqua 100-33Insulin Glargine/Lixisenatide33$39,229
Janumet XrSitagliptin Phos/Metformin Hcl31$36,277
ProliaDenosumab19$30,939
Bydureon BciseExenatide Microspheres19$27,957
MyrbetriqMirabegron35$22,810
XareltoRivaroxaban24$22,113
Repatha SureclickEvolocumab24$20,877
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$196$334,305213 claims
Lilly USA, LLCTrulicity, Mounjaro$113$200,262142 claims
Boehringer IngelheimJardiance$41$184,248156 claims
AmgenProlia$133$30,93919 claims
GSKTrelegy Ellipta, Breo Ellipta$55$23,90436 claims
AbbVieLinzess, Synthroid$30$23,766104 claims
AstraZenecaFarxiga, Symbicort$66$17,90727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Rosenberg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →